Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations. Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions).
Research Grade Motavizumab
Overview
Catalog No.
VK421036
Host species
Humanized
Species reactivity
HRSV-A
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Purity
>95% purity as determined by SDS-PAGE.
Clonality
Monoclonal
Isotype
IgG1, kappa
Applications
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Target
F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Purification
Protein A/G purified from cell culture supernatant.
Endotoxin level
Please contact the lab for this information.
Expression system
Mammalian Cells
Accession
P03420
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternative name
MEDI-524, NUMAX, NISTmAb, CR9503, CAS:677010-34-3
Note
For research use only. Not suitable for clinical or therapeutic use.
Description
Images
SEC-HPLC
SEC-HPLC detection for Research Grade Motavizumab.
Bioactivity
Detects F/Fusion glycoprotein F0 in indirect ELISAs.
SDS-PAGE
SDS-PAGE for Research Grade Motavizumab.